▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $437.27.
The current consensus among 2 investment analysts is to buy stock in Genmab A/S.
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.